Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6478-6487

  Hartmann, Evelyn ^b   Wollenberg, Barbara ^d   Rothenfusser, Simon ^a   Wagner, Moritz ^a   Wellisch, Daniela ^a   Mack, Brigitte ^b   Giese, Thomas ^c   Gires, Olivier ^a   Endres, Stefan ^a   Hartmann, Gunther ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL INFILTRATION; CELLULAR IMMUNITY; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DENDRITIC CELLS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-ALPHA; LYMPHOID TISSUE; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDES; T-LYMPHOCYTES; TH1 CELLS;

EID: 0141953994     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Ervin, T. J., Clark, J. R., Weichselbaum, R. R., Fallon, B. G., Miller, D., Fabian, R. L., Posner, M. R., Norris, C. M., Jr., Tuttle, S. A., and Schoenfeld, D. A. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol., 5: 10-20, 1987.
2. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.
3. Shin, D. M., and Lippman, S. M. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Semin. Oncol., 26: 100-105, 1999.
4. Wang, M. B., Lichtenstein, A., and Mickel, R. A. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg., 105: 517-527, 1991.
5. Hadden, J. W. The immunopharmacology of head and neck cancer: an update. Int. J. Immunopharmacol., 19: 629-644, 1997.
6. Wustrow, T. P., and Issing, W. J. Immune defects in patients with head and neck cancer. Anticancer Res., 13: 2507-2519, 1993.
7. Heimdal, J. H., Aarstad, H. J., and Olofsson, J. Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma. Laryngoscope, 110: 402-407, 2000.
8. Cortesina, G., De Stefani, A., Galeazzi, E., Cavallo, G. P., Badellino, F., Margarino, G., Jemma, C., and Forni, G. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br. J. Cancer, 69: 572-576, 1994.
9. De Stefani, A., Valente, G., Forni, G., Lerda, W., Ragona, R., and Cortesina, G. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J. Immunother., 19: 125-133, 1996.
10. Whiteside, T. L., Lelessier, E., Hirabayashi, H., Vitolo, D., Bryant, J., Barnes, L., Snyderman, C., Johnson, J. T., Myers, E., and Herberman, R. B. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res., 53: 5654-5662, 1993.
11. Mattijssen, V., De Mulder, P. H., De Graeff, A., Hupperets, P. S., Joosten, F., Ruiter, D. J., Bier, H., Palmer, P. A., and Van den Broek, P. Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann. Oncol., 5: 957-960, 1994.
12. Melioli, G., Margarino, G., Scala, M., Mercu, P., Bertoglio, S., Schenone, G., Barbaresi, M., Machi, A. M., Santi, L., and Badellino, F. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma. Laryngoscope, 102: 572-578, 1992.
13. Hamasaki, V. K., and Vokes, E. E. Interferons and other cytokines in head and neck cancer. Med. Oncol., 12: 23-33, 1995.
14. Wollenberg, B., Kastenbauer, E., Mundl, H., Schaumberg, J., Mayer, A., Andratschke, M., Lang, S., Pauli, C., Zeidler, R., Ihrler, S., Lohrs, Naujoks, K., and Rollston, R. Gene therapy-Phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum. Gene Ther., 10: 141-147, 1999.
15. Kirkwood, J. Cancer immunotherapy: the interferon α experience. Semin. Oncol., 29: 18-26, 2002.
16. Chehimi, J., Starr, S. E., Kawashima, H., Miller, D. S., Trinchieri, G., Perussia, B., and Bandyopadhyay, S. Dendritic cells and IFN-a-producing cells are two functionally distinct non-B, non-monocytic HLA-DR+ cell subsets in human peripheral blood. Immunology, 68: 488-490, 1989.
17. Abb, J., Abb, H., and Deinhardt, F. Phenotype of human alpha-interferon producing leucocytes identified by monoclonal antibodies. Clin. Exp. Immunol., 52: 179-184, 1983.
18. Fitzgerald-Bocarsly, P. Human natural interferon α producing cells. Pharmacol. Ther., 60: 39-62, 1993.
19. Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., and Colonna, M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med., 5: 919-923, 1999.
20. Galy, A., Christopherson, I., Ferlazzo, G., Liu, G., Spits, H., and Georgopoulos, K. Distinct signals control the hematopoiesis of lymphoid-related dendritic cells. Blood, 95: 128-137, 2000.
21. Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., and Liu, Y. J. The nature of the principal type I interferon-producing cells in human blood. Science (Wash. DC), 284: 1835-187, 1999.
22. Nakano, H., Yanagita, M., and Gunn, M. D. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med., 194: 1171-1178, 2001.
23. Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Briere, F., and Trinchieri, G. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol., 2: 1144-1150, 2001.
24. Bjorck, P. Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood, 98: 3520-3526, 2001.
25. Summers, K. L., Hock, B. D., McKenzie, J. L., and Hart, D. N. Phenotypic characterization of five dendritic cell subsets in human tonsils. Am. J. Pathol., 159: 285-295, 2001.
26. Pashenkov, M., Huang, Y. M., Kostulas, V., Haglund, M., Soderstrom, M., and Link, H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain, 124: 480-492, 2001.
27. Farkas, L., Beiske, K., Lund-Johansen, F., Brandtzaeg, P., and Jahnsen, F. L. Plasmacytoid dendritic cells (natural interferon α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol., 159: 237-243, 2001.
28. Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., Pustilnik, T., Curiel, D. T., Galanaud, P., Capron, F., Emilie, D., and Curiel, T. J. Stromal-derived factor-I in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med., 7: 1339-1346, 2001.
29. Jahnsen, F. L., Lund-Johansen, F., Dunne, J. F., Farkas, L., Haye, R., and Brandtzaeg, P. Experimentally induced recruitment of plasmacytoid (CD 123high) dendritic cells in human nasal allergy. J. Immunol., 165: 4062-4068, 2000.
30. Gilliet, M., and Liu, Y. J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med., 195: 695-704, 2002.
31. Krieg, A. M., and Wagner, H. Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol. Today, 21: 521-526, 2000.
32. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdorfer, B., Giese, T., Endres, S., and Hartmann, G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol., 168: 4531-4537, 2002.
33. Kadowaki, N., Antonenko, S., and Liu, Y. J. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c-type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol., 166: 2291-2295, 2001.
34. Bauer, M., Redecke, V., Ellwart, J. W., Scherer, B., Kremer, J. P., Wagner, H., and Lipford, G. B. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J. Immunol., 166: 5000-5007, 2001.
35. Krug, A., Towarowski, A., Britseh, S., Rothenfusser, S., Homung, V., Bals, R., Giese, T., Engelmann, H., Endres, S., Krieg, A. M., and Hartmann, G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol., 31: 3026-3037, 2001.
36. Kranzer, K., Bauer, M., Lipford, G. B., Heeg, K., Wagner, H., and Lang, R. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon γ production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology., 99: 170-178, 2000.
37. Rothenfusser, S., Homung, V., Krug, A., Towarowski, A., Krieg, A. M., Endres, S., and Hartmann, G. Distinct CpG oligonucleotide sequences activate human γ δ 8 T cells via interferon α/β. Eur. J. Immunol., 31: 3525-3534, 2001.
38. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z. K., Endres, S., Krieg, A. M., and Hartmann, G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J. Immunol., 31: 2154-2163, 2001.
39. Hartmann, G., Battiany, J., Poeck, H., Wagner, M., Kerkmann, M., Lubenow, N., Rolhenfusser, S., and Endres, S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol., 33: 1633-1641, 2003.
40. Verthelyi, D., Ishii, K., Gursel, M., Takeshita, F., and Klinman, D. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol., 166: 2372-2377, 2001.
41. Carpentier, A. F., Chen, L., Maltonti, F., and Delattre, J. Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res., 59: 5429-5432, 1999.
42. Carpentier, A. F., Xie, J., Mokhtari, K., and Delattre, J. Y. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin. Cancer Res., 6: 2469-2473, 2000.
43. Ballas, Z. K., Krieg, A. M., Warren, T., Rasmussen, W., Davis, H. L., Waldschmidt, M., and Weiner, G. J. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol., 167: 4878-4886, 2001.
44. Weiner, G. J. Immunostimulatory DNA sequences and cancer therapy. Springer Semin. Immunopathol., 22: 107-116, 2000.
45. Kawarada, Y., Ganss, R., Garbi, N., Sacher, T., Arnold, B., and Hammerling, G. J. NK- and CD8(+) T-cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol., 167: 5247-5253, 2001.
46. Heckelsmiller, K., Rall, K., Beck, S., Schlamp, A., Seiderer, J., Jahrsdörfer, B., Krug, A., Rothenfusser, S., Endres, S., and Hartmann, G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol., 169: 3892-3899, 2002.
47. Heckelsmiller, K., Beck, S., Rall, K., Sipos, B., Schlamp, A., Tuma, E., Rothenfusser, S., Endres, S., and Hartmann, G. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors which resist chemotherapy. Eur. J. Immunol., 32: 3235-3245, 2002.
48. Hartmann, G., Krug, A., Waller-Fontaine, K., and Endres, S. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol. Med., 2: 429-438, 1996.
49. Hartmann, G., and Krieg, A. M. Mechanism and function of a newly identified CpG DNA motif in human primary cells. J. Immunol., 164: 944-952, 2000.
50. Dzionek, A., Sohma, Y., Nagafune, J., Cella, M., Colonna, M., Facchetti, F., Gunther, G., Johnston, I., Lanzavecchia, A., Nagasaka, T., Okada, T., Vermi, W., Winkels, G., Yamamoto, T., Zysk, M., Yamaguchi, Y., and Schmitz, J. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med., 194: 1823-1834, 2001.
51. Cordell, J. L., Falini, B., Erber, W. N., Ghosh, A. K., Abdulaziz, Z., MacDonald, S., Pulford, K. A., Stein, H., and Mason, D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem., 32: 219-229, 1984.
52. Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D. W., and Schmitz, J. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol., 165: 6037-6046, 2000.
53. Olweus, J., BitMansour, A., Wamke, R., Thompson, P. A., Carballido, J., Picker, L. J., and Lund-Johansen, F. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl. Acad. Sci. USA, 94: 12551-12556, 1997.
54. Gary-Gouy, H., Lebon, P., and Dalloul, A. H. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J. Interferon Cytokine Res., 22: 653-659, 2002.
55. Jonasch, E., and Haluska, F. G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist, 6: 34-55, 2001.
56. Goldman, S. A., Baker, E., Weyant, R. J., Clarke, M. R., Myers, J. N., and Lotze, M. T. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch. Otolaryngol. Head Neck Surg., 124: 641-646, 1998.
57. Gallo, O., Bianchi, S., Giannini, A., Gallina, E., Libonati, G. A., and Fini-Storchi, O. Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngoscope, 101: 487-493, 1991.
58. Giannini, A., Bianchi, S., Messerini, L., Gallo, O., Gallina, E., Asprella Libonati, G., Olmi, P., and Zampi, G. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol. Res. Pract., 187: 496-502, 1991.
59. Reichert, T. E., Scheuer, C., Day, R., Wagner, W., and Whiteside, T. L. The number of intratumoral dendritic cells and ζ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer (Phila.), 91: 2136-2147, 2001.
60. Nestle, F. O., Burg, G., Fah, J., Wrone-Smith, T., and Nickoloff, B. J. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T-cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol., 150: 641-651, 1997.
61. Enk, A. H., Jonuleit, H., Saloga, J., and Knop, J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer, 73: 309-316, 1997.
62. Gabrilovich, D. I., Ciernik, I. F., and Carbone, D. P. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol., 170: 101-110, 1996.
63. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
64. Chaux, P., Favre, N., Martin, M., and Martin, F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer, 72: 619-624, 1997.
65. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
66. Almand, B., Resser, J. R., Lindman. B., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., and Gabrilovich, D. I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res., 6: 1755-1766, 2000.
67. Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot. M. C., Caux, C., and Blay, J. Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin- and macrophage colony-stimulating Factor. Blood, 92: 4778-4791, 1998.
68. Penna, G., Sozzani, S., and Adorini, L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J. Immunol., 167: 1862-1866, 2001.
69. Krug, A., Uppaluri, R. I., Facchetti, F., Domer, B. G., Sheehan, K., Schreiber, R. D., Cella, M., and Colonna, M. IFN-producing cells respond to CXCR3 ligands in the presence of CXCL 12 and secrete inflammatory chemokines upon activation. J. Immunol., 169: 6079-6083, 2002.
70. Rissoan, M. C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., de Waal Malefyt, R., and Liu, Y. J. Reciprocal control of T-helper cell and dendritic cell differentiation. Science (Wash. DC), 283: 1183-1186, 1999.
71. Liu, Y. J., and Blom, B. Introduction: TH2-inducing DC2 for immunotherapy. Blood, 95: 2482-2483, 2000.
72. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Imunol., 3: 196-200, 2002.
73. Busch VII. Verhandlungen ärztlicher Gesellschaften. Berliner Klnischc Wochenschrift, pp. 137-138, 1868.
74. Wiemann, B., and Starnes, C. O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther., 64: 529-564, 1994.